GCEX
10.5.2023 08:05:26 CEST | Business Wire | Press release
GCEX, a leading digital prime brokerage, has been granted permission from the Danish Financial Supervisory Authority (FSA) to operate as an investment firm.
The FSA license is a significant milestone for GCEX, enabling the rapidly growing firm to offer rolling Spot FX and CFDs to institutional clients in the EU.
Michael Aagaard, Managing Director, GCEX, Denmark said, “This is a major step forward for our business and we believe it will be a significant catalyst for growth in Europe. Brokers, fund managers, hedge funds and professional traders based in the EU will now have the peace of mind and reassurance of knowing that they are transacting with a credible firm which is regulated in their own jurisdiction.”
Lars Holst, CEO, GCEX added, “It is fantastic news that we now have access to the EU market as an investment firm regulated by the Danish FSA. Obtaining this FSA license involved an extremely stringent process in which we had to demonstrate our experience in financial services, the knowledge of our team, good governance and our strong focus on investor protection. It now opens the door for us to market to EU clients, presenting us with a major opportunity for further growth.”
“From the outset, we have been advocates of operating within strong regulatory environments. Our broader regulatory coverage reflects our ethos of providing a professional, reliable, trusted and robust service in order to be at the forefront of the industry.”
Headquartered in London with multiple offices around the globe including in Copenhagen, GCEX Group enables brokers, fund managers, hedge funds and professional traders to access deep liquidity in FX and CFDs. The firm also offers clients access to XplorDigital, a range of trading solutions.
True Global Ventures are investors in GCEX.
For further information, please visit www.gc.exchange or LinkedIn
Ends –
About GCEX
Founded in 2018, GCEX is a pioneering regulated digital prime brokerage with a best-of-breed digital asset and FX platform for institutional and professional clients. GCEX has partnerships with Tier 1 trusted Liquidity Providers, leading counterparties and regulated digital custody asset institutions. GCEX offers a wide range of products and technology solutions including White Labels.
GCEX is a trading name of GC Exchange Limited, GC Exchange Fondsmæglerselskab A/S, GC Exchange A/S and GC Exchange FZE.
GC Exchange Limited, a company incorporated in England and Wales (No11382809) with registered address at 75 King William Street, London, EC4N 7BE provides FX and CFDs products. GC Exchange Limited is authorised and regulated by the Financial Conduct Authority (FRN 828730).
Digital asset services are provided by GC Exchange A/S, a company incorporated in Denmark (CVR 43088777) with address at Amager Strandvej 390, 2770, Kastrup. GC Exchange A/S is authorised by the Danish Financial Supervisory Authority as a Currency Exchange (FTID 45020) and registered as a Virtual Asset Service Provider (FTID 17524) under the AML regulation.
GC Exchange Fondsmæglerselskab A/S, a company incorporated in Denmark (CVR 43345052) with address at Amager Strandvej 390, 2770, Kastrup. GC Exchange Fondsmæglerselskab A/S is authorised by the Danish Financial Supervisory Authority as an Investment Firm to offer FX and CFDs products.
GC Exchange FZE is incorporated as a Limited Liability Free Zone Establishment under the Dubai World Trade Center Authority with registration number 1896. GC Exchange FZE has been granted a Virtual Asset Service Provider License for the MVP phase by the Dubai Virtual Assets Regulatory Authority.
For further information, please visit www.gc.exchange or LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005921/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom